Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Antisense Therapeutics
 More »

  • Growing and Preparing Adult Stem Cells
    ... the ability to scale-up production is crucial to meeting the needs of cell therapeutics. ... The VIRxSYS trial utilized a replication-deficient virus with an antisense HIV payload to ...
    10-15-2013
  • Antisense Drugs Finally Turning the Corner
    Watching all this, anything but impassively, is Antisense Therapeutics (ATL). Founded in 2001 by Circadian Technologies, in collaboration with Isis, Australia-based ATL made the ...
    10-15-2013
  • GSK Adds Another Program to Isis Antisense Collab
    entered into an antisense collaboration potentially worth over $35 million that included up to six programs and focused on developing new therapeutics against targets for ...
    10-7-2013
  • 10 Biotechnologies Yet to Live Up to the Hype
    Antisense Anti-sepsis drugs Artificial blood substitutes Bioremediation HIV Vaccines Interleukin 2 Novel antibiotic agents Neurodegenerative and psychiatric disorder therapeutics ...
    6-5-2013
  • Isis Wins $10M After AstraZeneca Adds Prostate Cancer Drug to...
    ISIS-STAT3 Rx is among drug candidates that Isis and AstraZeneca agreed to develop under a collaboration designed to commercialize antisense therapeutics against five cancer ...
    6-3-2013
  • BMS, Santaris Make Potentially $100M+ mRNA-Targeting Deal
    overcomes the limitations of earlier antisense and siRNA technologies to deliver potent ... Santaris also have an alliance with miRagen Therapeutics going back to June of 2010 to ...
    4-16-2013
  • Roche and Isis Pharmaceuticals Set Sights on Huntington's
    This alliance combines Isis' antisense expertise with Roche's scientific knowhow in developing neurodegenerative therapeutics. In addition, Isis and Roche will be collaborating to ...
    4-8-2013
  • Mystery Rare Disease Drug Earns Isis $5M from GSK
    with the specific aim of applying Isis' antisense drug discovery platform toward the discovery and development of new therapeutics against targets for rare and serious ...
    2-19-2013
  • Study Details Methods for Improving Antisense Drugs
    Sarepta Therapeutics and Oregon State University explained how their methods aided in detecting one type of antisense therapeutics, phosphorodiamidate morpholine oligomers (PMO). ...
    1-31-2013
  • The New Economics of Orphan Diseases
    ... At least three compounds are in Phase III trials for rare diseases. An antisense ... a pharmacological chaperone for Fabry disease is in development with Amicus Therapeutics. ...
    1-1-2013
  • Antisense Making Sense to Isis Partners
    In the latest deal, AstraZeneca formed an alliance with the firm for the discovery and development of novel generation antisense therapeutics against five cancer targets. The ...
    12-11-2012
  • Novel Applications for Systems Biology
    ... of morpholino (antisense oligonucleotides used to inhibit specific transcripts). ... of the many genes involved in cardiovascular disease will aid in developing therapeutics. ...
    12-1-2012
  • RNAi's Enabling Powers
    ... indicated by the acquisition of Alvos Therapeutics, which has developed a clinically ... conventional antisense RNA molecules and RNAi compounds with the best features of both. ...
    11-1-2012
  • Advertorial: Asahi Kasei Bioprocess
    ... Synthesizing Therapeutic Oligonucleotides Nearly 250 programs are under development for therapeutics such as antisense oligos and siRNAs. Furthermore, in 2011, approximately $400 ...
    10-1-2012
  • Capitalizing on miRNA Research
    ... sense strand, short loop sequence, and antisense strand that, when expressed in cells, ... when our understanding of miRNA biology will inform the development of new therapeutics. ...
    6-15-2012
  • More »

    Journal Articles

  • Antisense Therapeutics in Oncology: Points to Consider in Their...
    SRIDHAR MANI, YUN GU, SCOTT WADLER, HOWARD FINGERT
    Nucleic Acid Therapeutics
    Antisense Therapeutics in Oncology: Points to Consider in Their Clinical Evaluation Nucleic Acid Therapeutics
  • Potential of Atelocollagen-Mediated Systemic Antisense Therapeutics...
    Koji Hanai, Tomoyo Kurokawa, Yoshiko Minakuchi, Miho Maeda, Shunji Nagahara, Teruo Miyata, Takahiro Ochiya, Akihiko Sano
    Human Gene Therapy and Part B: Methods
    Potential of Atelocollagen-Mediated Systemic Antisense Therapeutics for Inflammatory Disease Human Gene Therapy and Part B: Methods To study the possibility of using atelocollagen ...
  • ANTISENSE AND NUCLEIC ACID-BASED THERAPEUTICS: THE NEXT MILLENNIUM
    Arthur M. Krieg, C.A. Stein
    Nucleic Acid Therapeutics
    ANTISENSE AND NUCLEIC ACID-BASED THERAPEUTICS: THE NEXT MILLENNIUM Nucleic Acid Therapeutics
  • Modification of Alternative Splicing by Antisense Therapeutics
    Ryszard Kole, Marla Vacek, Tiffany Williams
    Nucleic Acid Therapeutics
    Modification of Alternative Splicing by Antisense Therapeutics Nucleic Acid Therapeutics

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll